nodes	percent_of_prediction	percent_of_DWPC	metapath
Atracurium—CHRND—pericardium—lung cancer	0.077	0.652	CbGeAlD
Atracurium—CHRND—Highly sodium permeable acetylcholine nicotinic receptors—CHRNB4—lung cancer	0.0229	0.0469	CbGpPWpGaD
Atracurium—CHRND—Highly sodium permeable acetylcholine nicotinic receptors—CHRNA3—lung cancer	0.0174	0.0356	CbGpPWpGaD
Atracurium—CHRNA1—Highly calcium permeable nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.0159	0.0326	CbGpPWpGaD
Atracurium—CHRNA2—mammary gland—lung cancer	0.0152	0.129	CbGeAlD
Atracurium—CHRNA2—Highly calcium permeable nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.0151	0.031	CbGpPWpGaD
Atracurium—CHRND—Presynaptic nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.0149	0.0305	CbGpPWpGaD
Atracurium—CHRNA1—Highly calcium permeable nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.0148	0.0303	CbGpPWpGaD
Atracurium—CHRND—respiratory system—lung cancer	0.0147	0.124	CbGeAlD
Atracurium—CHRNA2—Highly calcium permeable nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.0141	0.0288	CbGpPWpGaD
Atracurium—CHRND—Presynaptic nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.0138	0.0284	CbGpPWpGaD
Atracurium—CHRNA1—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.0136	0.0278	CbGpPWpGaD
Atracurium—CHRND—Acetylcholine Binding And Downstream Events—CHRNB4—lung cancer	0.0132	0.027	CbGpPWpGaD
Atracurium—CHRNA2—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.0129	0.0264	CbGpPWpGaD
Atracurium—CHRNA1—Presynaptic nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.0127	0.0259	CbGpPWpGaD
Atracurium—CHRNA1—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.0126	0.0258	CbGpPWpGaD
Atracurium—CHRND—Acetylcholine Binding And Downstream Events—CHRNA5—lung cancer	0.0122	0.0251	CbGpPWpGaD
Atracurium—CHRNA1—Highly calcium permeable nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.0121	0.0247	CbGpPWpGaD
Atracurium—CHRNA2—Presynaptic nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.012	0.0246	CbGpPWpGaD
Atracurium—CHRNA2—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.012	0.0246	CbGpPWpGaD
Atracurium—CHRNA1—Presynaptic nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.0118	0.0241	CbGpPWpGaD
Atracurium—CHRNA2—Highly calcium permeable nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.0115	0.0235	CbGpPWpGaD
Atracurium—CHRND—Presynaptic nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.0113	0.0231	CbGpPWpGaD
Atracurium—CHRNA1—Acetylcholine Binding And Downstream Events—CHRNB4—lung cancer	0.0112	0.0229	CbGpPWpGaD
Atracurium—CHRNA2—Presynaptic nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.0112	0.0229	CbGpPWpGaD
Atracurium—CHRNA2—Acetylcholine Binding And Downstream Events—CHRNB4—lung cancer	0.0106	0.0218	CbGpPWpGaD
Atracurium—CHRNA1—Acetylcholine Binding And Downstream Events—CHRNA5—lung cancer	0.0104	0.0213	CbGpPWpGaD
Atracurium—CHRNA1—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.0103	0.0211	CbGpPWpGaD
Atracurium—CHRND—Acetylcholine Binding And Downstream Events—CHRNA3—lung cancer	0.00997	0.0204	CbGpPWpGaD
Atracurium—CHRNA2—Acetylcholine Binding And Downstream Events—CHRNA5—lung cancer	0.00988	0.0202	CbGpPWpGaD
Atracurium—CHRNA2—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.00976	0.02	CbGpPWpGaD
Atracurium—CHRNA1—Presynaptic nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.00959	0.0197	CbGpPWpGaD
Atracurium—CHRNA2—Presynaptic nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.00911	0.0187	CbGpPWpGaD
Atracurium—CHRNA1—Acetylcholine Binding And Downstream Events—CHRNA3—lung cancer	0.00847	0.0174	CbGpPWpGaD
Atracurium—CHRNA2—Acetylcholine Binding And Downstream Events—CHRNA3—lung cancer	0.00805	0.0165	CbGpPWpGaD
Atracurium—CHRND—lung—lung cancer	0.00779	0.0659	CbGeAlD
Atracurium—CHRNB1—lymph node—lung cancer	0.00343	0.0291	CbGeAlD
Atracurium—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIK3—lung cancer	0.00256	0.00524	CbGpPWpGaD
Atracurium—Cardiovascular disorder—Etoposide—lung cancer	0.0025	0.00634	CcSEcCtD
Atracurium—Angioedema—Gefitinib—lung cancer	0.00247	0.00627	CcSEcCtD
Atracurium—Azotaemia—Methotrexate—lung cancer	0.00247	0.00626	CcSEcCtD
Atracurium—Nervous system disorder—Crizotinib—lung cancer	0.00238	0.00605	CcSEcCtD
Atracurium—Skin disorder—Crizotinib—lung cancer	0.00236	0.00599	CcSEcCtD
Atracurium—Flushing—Teniposide—lung cancer	0.00235	0.00597	CcSEcCtD
Atracurium—Hypertension—Pemetrexed—lung cancer	0.00235	0.00596	CcSEcCtD
Atracurium—Wheezing—Cisplatin—lung cancer	0.00233	0.0059	CcSEcCtD
Atracurium—Unspecified disorder of skin and subcutaneous tissue—Pemetrexed—lung cancer	0.0023	0.00584	CcSEcCtD
Atracurium—Unspecified disorder of skin and subcutaneous tissue—Gefitinib—lung cancer	0.00229	0.0058	CcSEcCtD
Atracurium—Anaphylactic shock—Pemetrexed—lung cancer	0.00222	0.00564	CcSEcCtD
Atracurium—Nervous system disorder—Pemetrexed—lung cancer	0.00218	0.00553	CcSEcCtD
Atracurium—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIK3—lung cancer	0.00217	0.00446	CbGpPWpGaD
Atracurium—Dyspnoea—Crizotinib—lung cancer	0.00217	0.0055	CcSEcCtD
Atracurium—Nervous system disorder—Gefitinib—lung cancer	0.00216	0.00549	CcSEcCtD
Atracurium—Skin disorder—Pemetrexed—lung cancer	0.00216	0.00548	CcSEcCtD
Atracurium—Skin disorder—Gefitinib—lung cancer	0.00214	0.00544	CcSEcCtD
Atracurium—Wheezing—Paclitaxel—lung cancer	0.00209	0.0053	CcSEcCtD
Atracurium—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB4—lung cancer	0.00208	0.00427	CbGpPWpGaD
Atracurium—Injury—Irinotecan—lung cancer	0.00208	0.00529	CcSEcCtD
Atracurium—Hypoxia—Methotrexate—lung cancer	0.00207	0.00525	CcSEcCtD
Atracurium—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIK3—lung cancer	0.00207	0.00423	CbGpPWpGaD
Atracurium—Hypotension—Gefitinib—lung cancer	0.00206	0.00523	CcSEcCtD
Atracurium—Muscular weakness—Vinorelbine—lung cancer	0.00205	0.0052	CcSEcCtD
Atracurium—Dyspnoea—Pemetrexed—lung cancer	0.00198	0.00503	CcSEcCtD
Atracurium—Anaphylactoid reaction—Irinotecan—lung cancer	0.00198	0.00502	CcSEcCtD
Atracurium—Bronchospasm—Vinorelbine—lung cancer	0.00197	0.00501	CcSEcCtD
Atracurium—Dyspnoea—Gefitinib—lung cancer	0.00197	0.00499	CcSEcCtD
Atracurium—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—lung cancer	0.00194	0.00397	CbGpPWpGaD
Atracurium—Anaphylactoid reaction—Gemcitabine—lung cancer	0.00193	0.00489	CcSEcCtD
Atracurium—CHRND—Transmission across Chemical Synapses—GRIK3—lung cancer	0.00192	0.00394	CbGpPWpGaD
Atracurium—Hypertension—Teniposide—lung cancer	0.0019	0.00483	CcSEcCtD
Atracurium—Connective tissue disorder—Erlotinib—lung cancer	0.00183	0.00463	CcSEcCtD
Atracurium—Cardiac arrest—Irinotecan—lung cancer	0.00182	0.00462	CcSEcCtD
Atracurium—Anaphylactoid reaction—Cisplatin—lung cancer	0.0018	0.00456	CcSEcCtD
Atracurium—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB4—lung cancer	0.00177	0.00363	CbGpPWpGaD
Atracurium—Urticaria—Pemetrexed—lung cancer	0.00176	0.00448	CcSEcCtD
Atracurium—Tachycardia—Teniposide—lung cancer	0.00176	0.00446	CcSEcCtD
Atracurium—Urticaria—Gefitinib—lung cancer	0.00175	0.00445	CcSEcCtD
Atracurium—Angiopathy—Topotecan—lung cancer	0.0017	0.00432	CcSEcCtD
Atracurium—CHRNA1—ErbB2/ErbB3 signaling events—ERBB3—lung cancer	0.0017	0.00348	CbGpPWpGaD
Atracurium—Injury—Paclitaxel—lung cancer	0.0017	0.00431	CcSEcCtD
Atracurium—Immune system disorder—Topotecan—lung cancer	0.0017	0.0043	CcSEcCtD
Atracurium—Mediastinal disorder—Topotecan—lung cancer	0.00169	0.00429	CcSEcCtD
Atracurium—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB4—lung cancer	0.00168	0.00345	CbGpPWpGaD
Atracurium—Hypotension—Teniposide—lung cancer	0.00168	0.00427	CcSEcCtD
Atracurium—Mediastinal disorder—Erlotinib—lung cancer	0.00167	0.00425	CcSEcCtD
Atracurium—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—lung cancer	0.00165	0.00338	CbGpPWpGaD
Atracurium—Anaphylactoid reaction—Etoposide—lung cancer	0.00165	0.00418	CcSEcCtD
Atracurium—Hypersensitivity—Pemetrexed—lung cancer	0.00164	0.00415	CcSEcCtD
Atracurium—CHRNA1—Transmission across Chemical Synapses—GRIK3—lung cancer	0.00163	0.00335	CbGpPWpGaD
Atracurium—Hypersensitivity—Gefitinib—lung cancer	0.00163	0.00413	CcSEcCtD
Atracurium—Erythema—Erlotinib—lung cancer	0.00162	0.0041	CcSEcCtD
Atracurium—Dyspnoea—Teniposide—lung cancer	0.0016	0.00407	CcSEcCtD
Atracurium—Bronchospasm—Gemcitabine—lung cancer	0.00159	0.00402	CcSEcCtD
Atracurium—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—lung cancer	0.00158	0.00324	CbGpPWpGaD
Atracurium—Connective tissue disorder—Vinorelbine—lung cancer	0.00158	0.00401	CcSEcCtD
Atracurium—Pruritus—Pemetrexed—lung cancer	0.00157	0.00399	CcSEcCtD
Atracurium—CHRND—Transmission across Chemical Synapses—CHRNB4—lung cancer	0.00157	0.00321	CbGpPWpGaD
Atracurium—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—lung cancer	0.00157	0.00321	CbGpPWpGaD
Atracurium—Pruritus—Gefitinib—lung cancer	0.00156	0.00396	CcSEcCtD
Atracurium—CHRNA2—Transmission across Chemical Synapses—GRIK3—lung cancer	0.00155	0.00318	CbGpPWpGaD
Atracurium—Rash—Crizotinib—lung cancer	0.00153	0.00389	CcSEcCtD
Atracurium—Dermatitis—Crizotinib—lung cancer	0.00153	0.00389	CcSEcCtD
Atracurium—Cardiac arrest—Etoposide—lung cancer	0.00151	0.00384	CcSEcCtD
Atracurium—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG11—lung cancer	0.00149	0.00306	CbGpPWpGaD
Atracurium—Angioedema—Topotecan—lung cancer	0.00149	0.00379	CcSEcCtD
Atracurium—Flushing—Vinorelbine—lung cancer	0.00149	0.00378	CcSEcCtD
Atracurium—Cardiac arrest—Paclitaxel—lung cancer	0.00148	0.00377	CcSEcCtD
Atracurium—CHRND—Neuronal System—GRIK3—lung cancer	0.00147	0.00302	CbGpPWpGaD
Atracurium—Convulsion—Vinblastine—lung cancer	0.00146	0.0037	CcSEcCtD
Atracurium—Angiopathy—Vinorelbine—lung cancer	0.00146	0.0037	CcSEcCtD
Atracurium—CHRND—Transmission across Chemical Synapses—CHRNA5—lung cancer	0.00146	0.00299	CbGpPWpGaD
Atracurium—Hypertension—Vinblastine—lung cancer	0.00145	0.00369	CcSEcCtD
Atracurium—Immune system disorder—Vinorelbine—lung cancer	0.00145	0.00368	CcSEcCtD
Atracurium—Mediastinal disorder—Vinorelbine—lung cancer	0.00145	0.00367	CcSEcCtD
Atracurium—Urticaria—Teniposide—lung cancer	0.00143	0.00363	CcSEcCtD
Atracurium—Rash—Pemetrexed—lung cancer	0.0014	0.00355	CcSEcCtD
Atracurium—Dermatitis—Pemetrexed—lung cancer	0.0014	0.00355	CcSEcCtD
Atracurium—Erythema—Vinorelbine—lung cancer	0.0014	0.00355	CcSEcCtD
Atracurium—Rash—Gefitinib—lung cancer	0.00139	0.00353	CcSEcCtD
Atracurium—Dermatitis—Gefitinib—lung cancer	0.00139	0.00353	CcSEcCtD
Atracurium—Unspecified disorder of skin and subcutaneous tissue—Topotecan—lung cancer	0.00138	0.00351	CcSEcCtD
Atracurium—Muscular weakness—Paclitaxel—lung cancer	0.00138	0.00349	CcSEcCtD
Atracurium—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—lung cancer	0.00137	0.00347	CcSEcCtD
Atracurium—Bronchospasm—Etoposide—lung cancer	0.00135	0.00344	CcSEcCtD
Atracurium—Bradycardia—Irinotecan—lung cancer	0.00135	0.00342	CcSEcCtD
Atracurium—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY1—lung cancer	0.00134	0.00275	CbGpPWpGaD
Atracurium—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—lung cancer	0.00134	0.00275	CbGpPWpGaD
Atracurium—Anaphylactic shock—Topotecan—lung cancer	0.00133	0.00338	CcSEcCtD
Atracurium—CHRNA1—Transmission across Chemical Synapses—CHRNB4—lung cancer	0.00133	0.00273	CbGpPWpGaD
Atracurium—Hypersensitivity—Teniposide—lung cancer	0.00133	0.00336	CcSEcCtD
Atracurium—Nervous system disorder—Topotecan—lung cancer	0.00131	0.00332	CcSEcCtD
Atracurium—Connective tissue disorder—Irinotecan—lung cancer	0.0013	0.0033	CcSEcCtD
Atracurium—Skin disorder—Topotecan—lung cancer	0.0013	0.00329	CcSEcCtD
Atracurium—Cardiovascular disorder—Doxorubicin—lung cancer	0.00129	0.00329	CcSEcCtD
Atracurium—Nervous system disorder—Erlotinib—lung cancer	0.00129	0.00328	CcSEcCtD
Atracurium—Skin disorder—Erlotinib—lung cancer	0.00128	0.00325	CcSEcCtD
Atracurium—Angioedema—Vinorelbine—lung cancer	0.00128	0.00324	CcSEcCtD
Atracurium—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—lung cancer	0.00128	0.00262	CbGpPWpGaD
Atracurium—Pruritus—Teniposide—lung cancer	0.00127	0.00323	CcSEcCtD
Atracurium—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG11—lung cancer	0.00127	0.0026	CbGpPWpGaD
Atracurium—Connective tissue disorder—Gemcitabine—lung cancer	0.00127	0.00322	CcSEcCtD
Atracurium—CHRNA2—Transmission across Chemical Synapses—CHRNB4—lung cancer	0.00127	0.00259	CbGpPWpGaD
Atracurium—CHRNA1—Neuronal System—GRIK3—lung cancer	0.00125	0.00257	CbGpPWpGaD
Atracurium—CHRNA1—Transmission across Chemical Synapses—CHRNA5—lung cancer	0.00124	0.00254	CbGpPWpGaD
Atracurium—Flushing—Irinotecan—lung cancer	0.00123	0.00312	CcSEcCtD
Atracurium—Bradycardia—Cisplatin—lung cancer	0.00122	0.00311	CcSEcCtD
Atracurium—CHRNA1—ErbB2/ErbB3 signaling events—MAP2K1—lung cancer	0.00121	0.00249	CbGpPWpGaD
Atracurium—Hypertension—Vinorelbine—lung cancer	0.00121	0.00306	CcSEcCtD
Atracurium—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG11—lung cancer	0.00121	0.00247	CbGpPWpGaD
Atracurium—Angiopathy—Irinotecan—lung cancer	0.0012	0.00305	CcSEcCtD
Atracurium—CHRND—Neuronal System—CHRNB4—lung cancer	0.0012	0.00246	CbGpPWpGaD
Atracurium—Immune system disorder—Irinotecan—lung cancer	0.0012	0.00304	CcSEcCtD
Atracurium—Mediastinal disorder—Irinotecan—lung cancer	0.00119	0.00303	CcSEcCtD
Atracurium—CHRNA2—Neuronal System—GRIK3—lung cancer	0.00119	0.00244	CbGpPWpGaD
Atracurium—Dyspnoea—Topotecan—lung cancer	0.00119	0.00302	CcSEcCtD
Atracurium—CHRND—Transmission across Chemical Synapses—CHRNA3—lung cancer	0.00119	0.00243	CbGpPWpGaD
Atracurium—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—lung cancer	0.00118	0.003	CcSEcCtD
Atracurium—Connective tissue disorder—Cisplatin—lung cancer	0.00118	0.003	CcSEcCtD
Atracurium—CHRNA2—Transmission across Chemical Synapses—CHRNA5—lung cancer	0.00118	0.00241	CbGpPWpGaD
Atracurium—Dyspnoea—Erlotinib—lung cancer	0.00118	0.00299	CcSEcCtD
Atracurium—Angiopathy—Gemcitabine—lung cancer	0.00117	0.00297	CcSEcCtD
Atracurium—Immune system disorder—Gemcitabine—lung cancer	0.00117	0.00296	CcSEcCtD
Atracurium—Mediastinal disorder—Gemcitabine—lung cancer	0.00116	0.00295	CcSEcCtD
Atracurium—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY1—lung cancer	0.00114	0.00234	CbGpPWpGaD
Atracurium—Anaphylactic shock—Vinorelbine—lung cancer	0.00114	0.0029	CcSEcCtD
Atracurium—Rash—Teniposide—lung cancer	0.00113	0.00288	CcSEcCtD
Atracurium—Dermatitis—Teniposide—lung cancer	0.00113	0.00288	CcSEcCtD
Atracurium—Bronchospasm—Docetaxel—lung cancer	0.00113	0.00286	CcSEcCtD
Atracurium—Erythema—Gemcitabine—lung cancer	0.00112	0.00285	CcSEcCtD
Atracurium—CHRND—Transmission across Chemical Synapses—GNG11—lung cancer	0.00112	0.0023	CbGpPWpGaD
Atracurium—Nervous system disorder—Vinorelbine—lung cancer	0.00112	0.00284	CcSEcCtD
Atracurium—CHRND—Neuronal System—CHRNA5—lung cancer	0.00112	0.00229	CbGpPWpGaD
Atracurium—Flushing—Cisplatin—lung cancer	0.00112	0.00283	CcSEcCtD
Atracurium—Tachycardia—Vinorelbine—lung cancer	0.00111	0.00283	CcSEcCtD
Atracurium—Skin disorder—Vinorelbine—lung cancer	0.00111	0.00281	CcSEcCtD
Atracurium—Bradycardia—Paclitaxel—lung cancer	0.0011	0.00279	CcSEcCtD
Atracurium—Immune system disorder—Cisplatin—lung cancer	0.00109	0.00276	CcSEcCtD
Atracurium—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY1—lung cancer	0.00108	0.00222	CbGpPWpGaD
Atracurium—Mediastinal disorder—Cisplatin—lung cancer	0.00108	0.00275	CcSEcCtD
Atracurium—CHRNA1—ErbB2/ErbB3 signaling events—RAF1—lung cancer	0.00108	0.00221	CbGpPWpGaD
Atracurium—Hypotension—Vinorelbine—lung cancer	0.00107	0.00271	CcSEcCtD
Atracurium—CHRNA1—ErbB2/ErbB3 signaling events—ERBB2—lung cancer	0.00107	0.00218	CbGpPWpGaD
Atracurium—Connective tissue disorder—Paclitaxel—lung cancer	0.00106	0.00269	CcSEcCtD
Atracurium—Urticaria—Topotecan—lung cancer	0.00106	0.00269	CcSEcCtD
Atracurium—CHRNA1—ErbB2/ErbB3 signaling events—PIK3CB—lung cancer	0.00105	0.00216	CbGpPWpGaD
Atracurium—CHRNA1—ErbB2/ErbB3 signaling events—MTOR—lung cancer	0.00105	0.00216	CbGpPWpGaD
Atracurium—Erythema—Cisplatin—lung cancer	0.00105	0.00266	CcSEcCtD
Atracurium—Flushing—Etoposide—lung cancer	0.00102	0.00259	CcSEcCtD
Atracurium—CHRNA1—Neuronal System—CHRNB4—lung cancer	0.00102	0.00209	CbGpPWpGaD
Atracurium—Dyspnoea—Vinorelbine—lung cancer	0.00102	0.00258	CcSEcCtD
Atracurium—Hypersensitivity—Vinblastine—lung cancer	0.00101	0.00257	CcSEcCtD
Atracurium—CHRND—Transmission across Chemical Synapses—ADCY1—lung cancer	0.00101	0.00207	CbGpPWpGaD
Atracurium—CHRNA1—Transmission across Chemical Synapses—CHRNA3—lung cancer	0.00101	0.00207	CbGpPWpGaD
Atracurium—Flushing—Paclitaxel—lung cancer	0.001	0.00254	CcSEcCtD
Atracurium—Angiopathy—Etoposide—lung cancer	0.000999	0.00254	CcSEcCtD
Atracurium—Hypertension—Irinotecan—lung cancer	0.000995	0.00253	CcSEcCtD
Atracurium—Immune system disorder—Etoposide—lung cancer	0.000995	0.00253	CcSEcCtD
Atracurium—Mediastinal disorder—Etoposide—lung cancer	0.000993	0.00252	CcSEcCtD
Atracurium—Anaphylactoid reaction—Methotrexate—lung cancer	0.000986	0.0025	CcSEcCtD
Atracurium—Hypersensitivity—Topotecan—lung cancer	0.000983	0.00249	CcSEcCtD
Atracurium—Angiopathy—Paclitaxel—lung cancer	0.00098	0.00249	CcSEcCtD
Atracurium—Immune system disorder—Paclitaxel—lung cancer	0.000976	0.00248	CcSEcCtD
Atracurium—Mediastinal disorder—Paclitaxel—lung cancer	0.000973	0.00247	CcSEcCtD
Atracurium—CHRNA2—Neuronal System—CHRNB4—lung cancer	0.00097	0.00199	CbGpPWpGaD
Atracurium—Hypertension—Gemcitabine—lung cancer	0.00097	0.00246	CcSEcCtD
Atracurium—CHRNA2—Transmission across Chemical Synapses—CHRNA3—lung cancer	0.000959	0.00197	CbGpPWpGaD
Atracurium—CHRNA1—Transmission across Chemical Synapses—GNG11—lung cancer	0.000955	0.00196	CbGpPWpGaD
Atracurium—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.00095	0.00241	CcSEcCtD
Atracurium—CHRNA1—Neuronal System—CHRNA5—lung cancer	0.000949	0.00195	CbGpPWpGaD
Atracurium—Pruritus—Topotecan—lung cancer	0.000944	0.00239	CcSEcCtD
Atracurium—Anaphylactic shock—Irinotecan—lung cancer	0.000941	0.00239	CcSEcCtD
Atracurium—Erythema—Paclitaxel—lung cancer	0.00094	0.00239	CcSEcCtD
Atracurium—CHRNA1—ErbB2/ErbB3 signaling events—JUN—lung cancer	0.000939	0.00193	CbGpPWpGaD
Atracurium—Pruritus—Erlotinib—lung cancer	0.000934	0.00237	CcSEcCtD
Atracurium—Nervous system disorder—Irinotecan—lung cancer	0.000923	0.00234	CcSEcCtD
Atracurium—Anaphylactic shock—Gemcitabine—lung cancer	0.000917	0.00233	CcSEcCtD
Atracurium—CHRND—Neuronal System—CHRNA3—lung cancer	0.00091	0.00187	CbGpPWpGaD
Atracurium—CHRNA2—Transmission across Chemical Synapses—GNG11—lung cancer	0.000907	0.00186	CbGpPWpGaD
Atracurium—Convulsion—Cisplatin—lung cancer	0.000907	0.0023	CcSEcCtD
Atracurium—Urticaria—Vinorelbine—lung cancer	0.000906	0.0023	CcSEcCtD
Atracurium—CHRNA2—Neuronal System—CHRNA5—lung cancer	0.000902	0.00185	CbGpPWpGaD
Atracurium—Connective tissue disorder—Docetaxel—lung cancer	0.0009	0.00228	CcSEcCtD
Atracurium—Nervous system disorder—Gemcitabine—lung cancer	0.000899	0.00228	CcSEcCtD
Atracurium—Skin disorder—Gemcitabine—lung cancer	0.00089	0.00226	CcSEcCtD
Atracurium—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000885	0.00225	CcSEcCtD
Atracurium—Hypotension—Irinotecan—lung cancer	0.000879	0.00223	CcSEcCtD
Atracurium—CHRND—Neuronal System—GNG11—lung cancer	0.00086	0.00176	CbGpPWpGaD
Atracurium—Angioedema—Paclitaxel—lung cancer	0.000859	0.00218	CcSEcCtD
Atracurium—CHRNA1—Transmission across Chemical Synapses—ADCY1—lung cancer	0.000859	0.00176	CbGpPWpGaD
Atracurium—Hypotension—Gemcitabine—lung cancer	0.000856	0.00217	CcSEcCtD
Atracurium—Anaphylactic shock—Cisplatin—lung cancer	0.000854	0.00217	CcSEcCtD
Atracurium—Anaphylactoid reaction—Doxorubicin—lung cancer	0.000853	0.00217	CcSEcCtD
Atracurium—Flushing—Docetaxel—lung cancer	0.00085	0.00216	CcSEcCtD
Atracurium—CHRNA1—ErbB2/ErbB3 signaling events—SRC—lung cancer	0.000843	0.00173	CbGpPWpGaD
Atracurium—Rash—Topotecan—lung cancer	0.000841	0.00213	CcSEcCtD
Atracurium—Hypersensitivity—Vinorelbine—lung cancer	0.000841	0.00213	CcSEcCtD
Atracurium—Dermatitis—Topotecan—lung cancer	0.00084	0.00213	CcSEcCtD
Atracurium—Dyspnoea—Irinotecan—lung cancer	0.000839	0.00213	CcSEcCtD
Atracurium—Nervous system disorder—Cisplatin—lung cancer	0.000838	0.00213	CcSEcCtD
Atracurium—Tachycardia—Cisplatin—lung cancer	0.000834	0.00212	CcSEcCtD
Atracurium—Rash—Erlotinib—lung cancer	0.000832	0.00211	CcSEcCtD
Atracurium—Dermatitis—Erlotinib—lung cancer	0.000831	0.00211	CcSEcCtD
Atracurium—Convulsion—Etoposide—lung cancer	0.000831	0.00211	CcSEcCtD
Atracurium—Angiopathy—Docetaxel—lung cancer	0.000831	0.00211	CcSEcCtD
Atracurium—Skin disorder—Cisplatin—lung cancer	0.00083	0.00211	CcSEcCtD
Atracurium—Hypertension—Etoposide—lung cancer	0.000828	0.0021	CcSEcCtD
Atracurium—Immune system disorder—Docetaxel—lung cancer	0.000827	0.0021	CcSEcCtD
Atracurium—Mediastinal disorder—Docetaxel—lung cancer	0.000825	0.00209	CcSEcCtD
Atracurium—Dyspnoea—Gemcitabine—lung cancer	0.000817	0.00207	CcSEcCtD
Atracurium—CHRNA2—Transmission across Chemical Synapses—ADCY1—lung cancer	0.000816	0.00167	CbGpPWpGaD
Atracurium—Convulsion—Paclitaxel—lung cancer	0.000815	0.00207	CcSEcCtD
Atracurium—CHRNA1—ErbB2/ErbB3 signaling events—STAT3—lung cancer	0.000813	0.00167	CbGpPWpGaD
Atracurium—Hypertension—Paclitaxel—lung cancer	0.000812	0.00206	CcSEcCtD
Atracurium—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000811	0.00206	CcSEcCtD
Atracurium—CHRNA1—ErbB2/ErbB3 signaling events—NRAS—lung cancer	0.000811	0.00166	CbGpPWpGaD
Atracurium—Pruritus—Vinorelbine—lung cancer	0.000807	0.00205	CcSEcCtD
Atracurium—Hypotension—Cisplatin—lung cancer	0.000798	0.00203	CcSEcCtD
Atracurium—Erythema—Docetaxel—lung cancer	0.000797	0.00202	CcSEcCtD
Atracurium—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000795	0.00202	CcSEcCtD
Atracurium—Cardiac arrest—Doxorubicin—lung cancer	0.000785	0.00199	CcSEcCtD
Atracurium—Anaphylactic shock—Etoposide—lung cancer	0.000783	0.00199	CcSEcCtD
Atracurium—CHRNA1—ErbB2/ErbB3 signaling events—MAPK3—lung cancer	0.000776	0.00159	CbGpPWpGaD
Atracurium—CHRNA1—Neuronal System—CHRNA3—lung cancer	0.000774	0.00159	CbGpPWpGaD
Atracurium—CHRND—Neuronal System—ADCY1—lung cancer	0.000774	0.00159	CbGpPWpGaD
Atracurium—Anaphylactic shock—Paclitaxel—lung cancer	0.000767	0.00195	CcSEcCtD
Atracurium—Tachycardia—Etoposide—lung cancer	0.000764	0.00194	CcSEcCtD
Atracurium—Dyspnoea—Cisplatin—lung cancer	0.000762	0.00193	CcSEcCtD
Atracurium—Skin disorder—Etoposide—lung cancer	0.00076	0.00193	CcSEcCtD
Atracurium—Nervous system disorder—Paclitaxel—lung cancer	0.000753	0.00191	CcSEcCtD
Atracurium—Tachycardia—Paclitaxel—lung cancer	0.000749	0.0019	CcSEcCtD
Atracurium—Skin disorder—Paclitaxel—lung cancer	0.000745	0.00189	CcSEcCtD
Atracurium—CHRNA2—Neuronal System—CHRNA3—lung cancer	0.000735	0.00151	CbGpPWpGaD
Atracurium—CHRNA1—Neuronal System—GNG11—lung cancer	0.000732	0.0015	CbGpPWpGaD
Atracurium—Hypotension—Etoposide—lung cancer	0.000731	0.00186	CcSEcCtD
Atracurium—Muscular weakness—Doxorubicin—lung cancer	0.000728	0.00185	CcSEcCtD
Atracurium—Rash—Vinorelbine—lung cancer	0.000719	0.00183	CcSEcCtD
Atracurium—Dermatitis—Vinorelbine—lung cancer	0.000719	0.00182	CcSEcCtD
Atracurium—Hypotension—Paclitaxel—lung cancer	0.000717	0.00182	CcSEcCtD
Atracurium—Dyspnoea—Etoposide—lung cancer	0.000698	0.00177	CcSEcCtD
Atracurium—CHRNA1—ErbB2/ErbB3 signaling events—KRAS—lung cancer	0.000698	0.00143	CbGpPWpGaD
Atracurium—CHRNA2—Neuronal System—GNG11—lung cancer	0.000695	0.00142	CbGpPWpGaD
Atracurium—Hypersensitivity—Irinotecan—lung cancer	0.000693	0.00176	CcSEcCtD
Atracurium—Convulsion—Docetaxel—lung cancer	0.000691	0.00175	CcSEcCtD
Atracurium—Hypertension—Docetaxel—lung cancer	0.000688	0.00175	CcSEcCtD
Atracurium—Dyspnoea—Paclitaxel—lung cancer	0.000684	0.00174	CcSEcCtD
Atracurium—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000674	0.00171	CcSEcCtD
Atracurium—CHRNA1—Neuronal System—ADCY1—lung cancer	0.000658	0.00135	CbGpPWpGaD
Atracurium—Anaphylactic shock—Docetaxel—lung cancer	0.00065	0.00165	CcSEcCtD
Atracurium—Pruritus—Gemcitabine—lung cancer	0.000648	0.00165	CcSEcCtD
Atracurium—CHRNA1—ErbB2/ErbB3 signaling events—PIK3CA—lung cancer	0.000641	0.00131	CbGpPWpGaD
Atracurium—Nervous system disorder—Docetaxel—lung cancer	0.000638	0.00162	CcSEcCtD
Atracurium—Tachycardia—Docetaxel—lung cancer	0.000635	0.00161	CcSEcCtD
Atracurium—Skin disorder—Docetaxel—lung cancer	0.000632	0.0016	CcSEcCtD
Atracurium—Hypersensitivity—Cisplatin—lung cancer	0.000629	0.0016	CcSEcCtD
Atracurium—CHRNA2—Neuronal System—ADCY1—lung cancer	0.000625	0.00128	CbGpPWpGaD
Atracurium—Urticaria—Etoposide—lung cancer	0.000622	0.00158	CcSEcCtD
Atracurium—Urticaria—Paclitaxel—lung cancer	0.00061	0.00155	CcSEcCtD
Atracurium—Hypotension—Docetaxel—lung cancer	0.000608	0.00154	CcSEcCtD
Atracurium—Angiopathy—Methotrexate—lung cancer	0.000599	0.00152	CcSEcCtD
Atracurium—Immune system disorder—Methotrexate—lung cancer	0.000596	0.00151	CcSEcCtD
Atracurium—Mediastinal disorder—Methotrexate—lung cancer	0.000595	0.00151	CcSEcCtD
Atracurium—Rash—Irinotecan—lung cancer	0.000593	0.00151	CcSEcCtD
Atracurium—CHRNA1—ErbB2/ErbB3 signaling events—HRAS—lung cancer	0.000593	0.00122	CbGpPWpGaD
Atracurium—Dermatitis—Irinotecan—lung cancer	0.000593	0.0015	CcSEcCtD
Atracurium—Bradycardia—Doxorubicin—lung cancer	0.000582	0.00148	CcSEcCtD
Atracurium—Dyspnoea—Docetaxel—lung cancer	0.00058	0.00147	CcSEcCtD
Atracurium—Rash—Gemcitabine—lung cancer	0.000578	0.00147	CcSEcCtD
Atracurium—Dermatitis—Gemcitabine—lung cancer	0.000577	0.00147	CcSEcCtD
Atracurium—Hypersensitivity—Etoposide—lung cancer	0.000577	0.00146	CcSEcCtD
Atracurium—Erythema—Methotrexate—lung cancer	0.000574	0.00146	CcSEcCtD
Atracurium—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—lung cancer	0.000568	0.00116	CbGpPWpGaD
Atracurium—Hypersensitivity—Paclitaxel—lung cancer	0.000565	0.00143	CcSEcCtD
Atracurium—Connective tissue disorder—Doxorubicin—lung cancer	0.000561	0.00143	CcSEcCtD
Atracurium—Pruritus—Etoposide—lung cancer	0.000554	0.00141	CcSEcCtD
Atracurium—Pruritus—Paclitaxel—lung cancer	0.000543	0.00138	CcSEcCtD
Atracurium—Rash—Cisplatin—lung cancer	0.000539	0.00137	CcSEcCtD
Atracurium—Dermatitis—Cisplatin—lung cancer	0.000538	0.00137	CcSEcCtD
Atracurium—Flushing—Doxorubicin—lung cancer	0.00053	0.00135	CcSEcCtD
Atracurium—CHRNA1—ErbB2/ErbB3 signaling events—AKT1—lung cancer	0.000524	0.00107	CbGpPWpGaD
Atracurium—Angiopathy—Doxorubicin—lung cancer	0.000518	0.00132	CcSEcCtD
Atracurium—Immune system disorder—Doxorubicin—lung cancer	0.000516	0.00131	CcSEcCtD
Atracurium—Mediastinal disorder—Doxorubicin—lung cancer	0.000515	0.00131	CcSEcCtD
Atracurium—Convulsion—Methotrexate—lung cancer	0.000498	0.00126	CcSEcCtD
Atracurium—Erythema—Doxorubicin—lung cancer	0.000497	0.00126	CcSEcCtD
Atracurium—Rash—Etoposide—lung cancer	0.000493	0.00125	CcSEcCtD
Atracurium—Dermatitis—Etoposide—lung cancer	0.000493	0.00125	CcSEcCtD
Atracurium—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000486	0.00123	CcSEcCtD
Atracurium—Rash—Paclitaxel—lung cancer	0.000484	0.00123	CcSEcCtD
Atracurium—Dermatitis—Paclitaxel—lung cancer	0.000483	0.00123	CcSEcCtD
Atracurium—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—lung cancer	0.000483	0.00099	CbGpPWpGaD
Atracurium—Hypersensitivity—Docetaxel—lung cancer	0.000479	0.00122	CcSEcCtD
Atracurium—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—lung cancer	0.000476	0.000975	CbGpPWpGaD
Atracurium—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—lung cancer	0.000474	0.000972	CbGpPWpGaD
Atracurium—Anaphylactic shock—Methotrexate—lung cancer	0.000469	0.00119	CcSEcCtD
Atracurium—Pruritus—Docetaxel—lung cancer	0.00046	0.00117	CcSEcCtD
Atracurium—Nervous system disorder—Methotrexate—lung cancer	0.00046	0.00117	CcSEcCtD
Atracurium—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—lung cancer	0.000459	0.00094	CbGpPWpGaD
Atracurium—Skin disorder—Methotrexate—lung cancer	0.000455	0.00116	CcSEcCtD
Atracurium—Hypotension—Methotrexate—lung cancer	0.000438	0.00111	CcSEcCtD
Atracurium—Convulsion—Doxorubicin—lung cancer	0.000431	0.00109	CcSEcCtD
Atracurium—Hypertension—Doxorubicin—lung cancer	0.000429	0.00109	CcSEcCtD
Atracurium—CHRND—Transmission across Chemical Synapses—BRAF—lung cancer	0.000427	0.000875	CbGpPWpGaD
Atracurium—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000421	0.00107	CcSEcCtD
Atracurium—Dyspnoea—Methotrexate—lung cancer	0.000418	0.00106	CcSEcCtD
Atracurium—Rash—Docetaxel—lung cancer	0.00041	0.00104	CcSEcCtD
Atracurium—Dermatitis—Docetaxel—lung cancer	0.00041	0.00104	CcSEcCtD
Atracurium—Anaphylactic shock—Doxorubicin—lung cancer	0.000406	0.00103	CcSEcCtD
Atracurium—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—lung cancer	0.000405	0.000829	CbGpPWpGaD
Atracurium—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—lung cancer	0.000403	0.000827	CbGpPWpGaD
Atracurium—Nervous system disorder—Doxorubicin—lung cancer	0.000398	0.00101	CcSEcCtD
Atracurium—Tachycardia—Doxorubicin—lung cancer	0.000396	0.00101	CcSEcCtD
Atracurium—Skin disorder—Doxorubicin—lung cancer	0.000394	0.001	CcSEcCtD
Atracurium—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—lung cancer	0.000384	0.000788	CbGpPWpGaD
Atracurium—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—lung cancer	0.000383	0.000785	CbGpPWpGaD
Atracurium—Hypotension—Doxorubicin—lung cancer	0.000379	0.000963	CcSEcCtD
Atracurium—Urticaria—Methotrexate—lung cancer	0.000372	0.000945	CcSEcCtD
Atracurium—CHRNA1—Transmission across Chemical Synapses—BRAF—lung cancer	0.000363	0.000744	CbGpPWpGaD
Atracurium—Dyspnoea—Doxorubicin—lung cancer	0.000362	0.000919	CcSEcCtD
Atracurium—CHRND—Transmission across Chemical Synapses—MDM2—lung cancer	0.000358	0.000733	CbGpPWpGaD
Atracurium—CHRND—Transmission across Chemical Synapses—RAF1—lung cancer	0.000357	0.000731	CbGpPWpGaD
Atracurium—Hypersensitivity—Methotrexate—lung cancer	0.000345	0.000877	CcSEcCtD
Atracurium—CHRNA2—Transmission across Chemical Synapses—BRAF—lung cancer	0.000345	0.000707	CbGpPWpGaD
Atracurium—Pruritus—Methotrexate—lung cancer	0.000332	0.000842	CcSEcCtD
Atracurium—CHRND—Neuronal System—BRAF—lung cancer	0.000327	0.000671	CbGpPWpGaD
Atracurium—Urticaria—Doxorubicin—lung cancer	0.000322	0.000818	CcSEcCtD
Atracurium—CHRNA1—Transmission across Chemical Synapses—MDM2—lung cancer	0.000304	0.000624	CbGpPWpGaD
Atracurium—CHRNA1—Transmission across Chemical Synapses—RAF1—lung cancer	0.000303	0.000621	CbGpPWpGaD
Atracurium—Hypersensitivity—Doxorubicin—lung cancer	0.000299	0.000759	CcSEcCtD
Atracurium—Rash—Methotrexate—lung cancer	0.000296	0.00075	CcSEcCtD
Atracurium—Dermatitis—Methotrexate—lung cancer	0.000295	0.00075	CcSEcCtD
Atracurium—CHRNA2—Transmission across Chemical Synapses—MDM2—lung cancer	0.000289	0.000592	CbGpPWpGaD
Atracurium—CHRNA2—Transmission across Chemical Synapses—RAF1—lung cancer	0.000288	0.00059	CbGpPWpGaD
Atracurium—Pruritus—Doxorubicin—lung cancer	0.000287	0.000729	CcSEcCtD
Atracurium—CHRNA1—Neuronal System—BRAF—lung cancer	0.000278	0.00057	CbGpPWpGaD
Atracurium—CHRND—Neuronal System—MDM2—lung cancer	0.000274	0.000562	CbGpPWpGaD
Atracurium—CHRND—Neuronal System—RAF1—lung cancer	0.000273	0.00056	CbGpPWpGaD
Atracurium—CHRNA2—Neuronal System—BRAF—lung cancer	0.000264	0.000542	CbGpPWpGaD
Atracurium—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—lung cancer	0.000261	0.000535	CbGpPWpGaD
Atracurium—Rash—Doxorubicin—lung cancer	0.000256	0.00065	CcSEcCtD
Atracurium—Dermatitis—Doxorubicin—lung cancer	0.000256	0.000649	CcSEcCtD
Atracurium—CHRNA1—Neuronal System—MDM2—lung cancer	0.000233	0.000478	CbGpPWpGaD
Atracurium—CHRNA1—Neuronal System—RAF1—lung cancer	0.000232	0.000476	CbGpPWpGaD
Atracurium—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—lung cancer	0.000222	0.000455	CbGpPWpGaD
Atracurium—CHRNA2—Neuronal System—MDM2—lung cancer	0.000221	0.000454	CbGpPWpGaD
Atracurium—CHRNA2—Neuronal System—RAF1—lung cancer	0.000221	0.000452	CbGpPWpGaD
Atracurium—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—lung cancer	0.000211	0.000432	CbGpPWpGaD
Atracurium—CHRND—Transmission across Chemical Synapses—HRAS—lung cancer	0.000196	0.000402	CbGpPWpGaD
Atracurium—CHRNA1—Transmission across Chemical Synapses—HRAS—lung cancer	0.000167	0.000342	CbGpPWpGaD
Atracurium—CHRNA2—Transmission across Chemical Synapses—HRAS—lung cancer	0.000159	0.000325	CbGpPWpGaD
Atracurium—CHRND—Neuronal System—HRAS—lung cancer	0.00015	0.000308	CbGpPWpGaD
Atracurium—CHRNA1—Neuronal System—HRAS—lung cancer	0.000128	0.000262	CbGpPWpGaD
Atracurium—CHRNA2—Neuronal System—HRAS—lung cancer	0.000122	0.000249	CbGpPWpGaD
